159 related articles for article (PubMed ID: 37417298)
1. Application of precision medicine based on next-generation sequencing and immunohistochemistry in ovarian cancer: a real-world experience.
Kim YN; Chung YS; Lee JH; Park E; Lee ST; Kim S; Lee JY
J Gynecol Oncol; 2023 Nov; 34(6):e70. PubMed ID: 37417298
[TBL] [Abstract][Full Text] [Related]
2. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
Liu J; Liu Y
Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773
[TBL] [Abstract][Full Text] [Related]
3. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585
[TBL] [Abstract][Full Text] [Related]
4. Mutational landscape of homologous recombination-related genes in small-cell lung cancer.
Wu S; Zhang Y; Zhang Y; Chen LH; Ouyang HF; Xu X; Du Y; Ti XY
Cancer Med; 2023 Feb; 12(4):4486-4495. PubMed ID: 36053931
[TBL] [Abstract][Full Text] [Related]
5. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
6. Genetic Variants and Tumor Immune Microenvironment: Clues for Targeted Therapies in Inflammatory Breast Cancer (IBC).
Gong Y; Nagarathinam R; Arisi MF; Gerratana L; Winn JS; Slifker M; Pei J; Cai KQ; Hasse Z; Obeid E; Noriega J; Sebastiano C; Ross E; Alpaugh K; Cristofanilli M; Fernandez SV
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445631
[TBL] [Abstract][Full Text] [Related]
7. Integrating a Next Generation Sequencing Panel into Clinical Practice in Ovarian Cancer.
Lee YJ; Kim D; Kim HS; Na K; Lee JY; Nam EJ; Kim SW; Kim S; Kim YT
Yonsei Med J; 2019 Oct; 60(10):914-923. PubMed ID: 31538426
[TBL] [Abstract][Full Text] [Related]
8. Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials.
Meagher NS; Schuster K; Voss A; Budden T; Pang CNI; deFazio A; Ramus SJ; Friedlander ML
Gynecol Oncol; 2018 Sep; 150(3):527-533. PubMed ID: 30054102
[TBL] [Abstract][Full Text] [Related]
9. Next-Generation Sequencing in Breast Cancer Patients: Real-World Data for Precision Medicine.
Lee H; Cho YA; Kim DG; Cho EY
Cancer Res Treat; 2024 Jan; 56(1):149-161. PubMed ID: 37591784
[TBL] [Abstract][Full Text] [Related]
10. Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling.
Gargano SM; Senarathne W; Feldman R; Florento E; Stafford P; Swensen J; Vranic S; Gatalica Z
Cancer Med; 2019 Dec; 8(17):7322-7329. PubMed ID: 31609094
[TBL] [Abstract][Full Text] [Related]
11. [Comprehensive assessment of mismatch repair and microsatellite instability status in molecular classification of endometrial carcinoma].
Liu Y; Wang YX; Sun XJ; Ting X; Wu R; Liu XD; Liu CR
Zhonghua Fu Chan Ke Za Zhi; 2023 Oct; 58(10):755-765. PubMed ID: 37849256
[No Abstract] [Full Text] [Related]
12. Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer.
Kim HS; Lee H; Shin SJ; Beom SH; Jung M; Bae S; Lee EY; Park KH; Choi YY; Son T; Kim HI; Cheong JH; Hyung WJ; Park JC; Shin SK; Lee SK; Lee YC; Koom WS; Lim JS; Chung HC; Noh SH; Rha SY; Kim H; Paik S
Oncotarget; 2017 Jun; 8(24):38389-38398. PubMed ID: 28418920
[TBL] [Abstract][Full Text] [Related]
13. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients.
Vanderwalde A; Spetzler D; Xiao N; Gatalica Z; Marshall J
Cancer Med; 2018 Mar; 7(3):746-756. PubMed ID: 29436178
[TBL] [Abstract][Full Text] [Related]
14. Validation of multi-gene panel next-generation sequencing for the detection of BRCA mutation in formalin-fixed, paraffin-embedded epithelial ovarian cancer tissues.
Kim ET; Jeong HE; Yoon HJ; Kim KH; Suh DS
Taiwan J Obstet Gynecol; 2023 Jan; 62(1):66-70. PubMed ID: 36720553
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive genomic profiling reveals ubiquitous KRAS mutations and frequent PIK3CA mutations in ovarian seromucinous borderline tumor.
Wu RC; Chen SJ; Chen HC; Tan KT; Jung SM; Lin CY; Chao AS; Huang KG; Chou HH; Chang TC; Chao A; Lai CH
Mod Pathol; 2020 Dec; 33(12):2534-2543. PubMed ID: 32616873
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive genomic and immunohistochemical profiles and outcomes of immunotherapy in patients with recurrent or advanced cervical cancer.
Kim YN; Lee K; Park E; Park J; Lee YJ; Nam EJ; Kim SW; Kim S; Kim YT; Lee JY
Front Oncol; 2023; 13():1156973. PubMed ID: 37256181
[TBL] [Abstract][Full Text] [Related]
17. Identification of molecular targets in vulvar cancers.
Palisoul ML; Mullen MM; Feldman R; Thaker PH
Gynecol Oncol; 2017 Aug; 146(2):305-313. PubMed ID: 28536037
[TBL] [Abstract][Full Text] [Related]
18. Mismatch Repair Deficiency in Ovarian Carcinoma: Frequency, Causes, and Consequences.
Leskela S; Romero I; Cristobal E; Pérez-Mies B; Rosa-Rosa JM; Gutierrez-Pecharroman A; Caniego-Casas T; Santón A; Ojeda B; López-Reig R; Palacios-Berraquero ML; García Á; Ibarra J; Hakim S; Guarch R; López-Guerrero JA; Poveda A; Palacios J
Am J Surg Pathol; 2020 May; 44(5):649-656. PubMed ID: 32294063
[TBL] [Abstract][Full Text] [Related]
19. The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers.
Barrett MT; Lenkiewicz E; Malasi S; Basu A; Yearley JH; Annamalai L; McCullough AE; Kosiorek HE; Narang P; Wilson Sayres MA; Chen M; Anderson KS; Pockaj BA
Breast Cancer Res; 2018 Jul; 20(1):71. PubMed ID: 29996881
[TBL] [Abstract][Full Text] [Related]
20. Germline and somatic variants in ovarian carcinoma: A next-generation sequencing (NGS) analysis.
Andrikopoulou A; Zografos E; Apostolidou K; Kyriazoglou A; Papatheodoridi AM; Kaparelou M; Koutsoukos K; Liontos M; Dimopoulos MA; Zagouri F
Front Oncol; 2022; 12():1030786. PubMed ID: 36531003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
